{"id":160729,"date":"2025-06-03T01:53:14","date_gmt":"2025-06-03T01:53:14","guid":{"rendered":"https:\/\/www.europesays.com\/de\/160729\/"},"modified":"2025-06-03T01:53:14","modified_gmt":"2025-06-03T01:53:14","slug":"alphavalue-baader-europe-senkt-kursziel-fuer-h-lundbeck-aufgrund-veraenderter-eps-erwartungen","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/de\/160729\/","title":{"rendered":"AlphaValue\/Baader Europe senkt Kursziel f\u00fcr H. Lundbeck aufgrund ver\u00e4nderter EPS-Erwartungen"},"content":{"rendered":"<p><img decoding=\"async\" class=\"pr-5\" height=\"30\" alt=\"Logo H. Lundbeck A\/S\" onerror=\"this.onerror=null;this.style.display = 'none'\" src=\"https:\/\/www.europesays.com\/de\/wp-content\/uploads\/2025\/06\/instruments-squared-138910356.png\"\/><br \/>\n        H Lundbeck A\/S ist ein in D\u00e4nemark ans\u00e4ssiges Unternehmen, das in der pharmazeutischen Industrie t\u00e4tig ist. Es besch\u00e4ftigt sich mit der Erforschung, Entwicklung, Herstellung und Vermarktung von Arzneimitteln zur Behandlung von Hirnerkrankungen wie Alzheimer, bipolare St\u00f6rungen, Depressionen, Epilepsie, Chorea Huntington, Parkinson und Schizophrenie. Sein Produktportfolio umfasst: Cipralex zur Behandlung von Depressionen und Angstzust\u00e4nden, Ebixa zur Behandlung der Alzheimer-Krankheit, Azilect zur Behandlung der Parkinson-Krankheit, Xenazine zur Behandlung der Huntington-Krankheit und Sabril zur Behandlung von Epilepsie, um nur einige zu nennen. Das Unternehmen ist \u00fcber eine Reihe von Tochtergesellschaften t\u00e4tig, darunter Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia und Lundbeck LLC.<\/p>\n","protected":false},"excerpt":{"rendered":"H Lundbeck A\/S ist ein in D\u00e4nemark ans\u00e4ssiges Unternehmen, das in der pharmazeutischen Industrie t\u00e4tig ist. Es besch\u00e4ftigt&hellip;\n","protected":false},"author":2,"featured_media":15564,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3933],"tags":[331,332,665,548,663,158,3934,3935,13,14,15,12],"class_list":{"0":"post-160729","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-eu","8":"tag-aktuelle-nachrichten","9":"tag-aktuelle-news","10":"tag-boerse","11":"tag-eu","12":"tag-europa","13":"tag-europaeische-union","14":"tag-europe","15":"tag-european-union","16":"tag-headlines","17":"tag-nachrichten","18":"tag-news","19":"tag-schlagzeilen"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@de\/114616939521661437","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts\/160729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/comments?post=160729"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts\/160729\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/media\/15564"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/media?parent=160729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/categories?post=160729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/tags?post=160729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}